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Therapeutic implications and new perspectives for essential
hypertension and renal damage. The kidney can suffer the
consequences of a persistently elevated blood pressure. In fact
end-stage renal failure caused by essential hypertension appears
to be one of the most prevalent etiologies in patients entering a
dialysis program. Blood pressure control is needed in order to
prevent the progressive loss of renal function. Target blood
pressure control has been established at values as low as 125/75
mm Hg for patients with proteinuria above 1 g/day. Attainment of
this target level usually requires the combination of two or more
drugs. However, the possibility that differences exist among the
different classes of antihypertensive drugs beyond their capacity
to simply lower blood pressure remains to be clearly elucidated.
The fact that the presence of chronic renal failure is also
accompanied by an enhanced cardiovascular risk potentiates the
need to explore the renoprotective and cardiovascular protective
capacity of the different classes of antihypertensive drugs, in
patients with essential hypertension and some degree of renal
involvement, characterized by the presence of microalbuminuria,
proteinuria and/or an elevated serum creatinine.
The kidney and high blood pressure are closely related.
A defective capacity to normally handle the sodium content
in the diet seems to be the renal mechanism participating in
the initial rise in blood pressure [1]. Different theories have
tried to explain how the kidney, through an intrinsic defect,
participates in the origin of arterial hypertension. Among
them are a defect of the tubular epithelial membrane
impeding the normal handling of sodium [2], a congenital
reduction in the number of nephrons or in the filtration
area [3], and a heterogeneity in the population of nephrons,
with ischemic and non-ischemic nephrons that disturb the
normal equilibrium between sodium intake and output [4].
The most plausible cause for the derangement in the
renal capacity to excrete sodium is the presence of renal
vasoconstriction that facilitates sodium retention [5]. How-
ever, renal vasoconstriction probably does not represent an
intrinsic renal defect, but the renal consequence of the
systemic vascular adaptation to the hypertensive process
[6]. This possibility does not exclude the pivotal role of the
kidney in the development of hypertension, neither does it
exclude the hypothesis that an increase in blood pressure is
needed to maintain the glomerular filtration rate and
sodium excretion within normal limits [7]. Interestingly,
renal vasoconstriction is functional in the initial stages of
the disease and remains constant thereafter as a conse-
quence of the nephrosclerosis secondary to persistently
elevated blood pressure [8–10].
RENAL DAMAGE IN PRIMARY HYPERTENSION
Arterial hypertension leads to renal insufficiency via two
possible pathways [11]. The traditional view is that arterial
hypertension produces renal failure as a consequence of
glomerular ischemia induced by damage to preglomerular
arteries and arterioles, leading to progressive luminal nar-
rowing and to a fall in glomerular blood flow. A comple-
mentary view is that hypertensive renal damage depends on
transmission of the elevated systemic pressure to the glo-
meruli, inducing glomerular capillary hyperperfusion and
hypertension, which in turn causes glomerular structural
injury and progressive loss of renal function. The presence
of an increased rate of glomerular filtration rate per
nephron, with decreased renal blood flow but an un-
changed total glomerular filtration rate, was reported by
Birkenha¨ger and Schalekamp [12]. These authors proposed
that hypertension is accompanied by an accelerated de-
struction of renal arterioles and glomeruli. As a conse-
quence of the elevated systemic pressure, the afferent
arterioles may be mechanically dilated, allowing transmis-
sion of the elevated systemic pressure to the glomeruli and
thus increasing the glomerular filtration rate per nephron,
which maintains the overall glomerular filtration rate.
In the absence of antihypertensive treatment, renal in-
volvement was very frequent in primary hypertension.
Perera described that proteinuria was present in 42%, and
chronic renal failure in 18% of a series of 500 patients
followed until death [13]. With the advent of antihyperten-
sive therapy the cardiovascular and renal prognosis of
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hypertensive patients improved dramatically. The meta-
analysis published by Collins et al [14], that was recently
updated to include the results of the studies on antihyper-
tensive therapy in the elderly [15], has definitely shown that
antihypertensive treatment has lowered the prevalence of
stroke in the amount expected for the level of blood
pressure decrease. By contrast, the incidence of myocardial
infarction did not attain the expected fall. Although these
studies did not include information regarding renal insuf-
ficiency, the prognosis has been considered by some au-
thors as excellent when arterial hypertension is treated,
with a very small percentage of patients (,2%) developing
chronic renal failure [16]. However, some evidence indi-
cates that the prognosis of renal function is not as good in
essential hypertensive patients [17–20]. There is: (1) an
increasing prevalence of nephrosclerosis as a cause of
end-stage renal failure in patients entering dialysis pro-
grams in both the U.S. and Europe; (2) a progressive
decline in renal function in a significant percentage of
treated hypertensive patients; (3) an association between
blood pressure and serum creatinine that is consistent with
the hypothesis that blood pressure elevations, even below
the hypertensive range, may induce early renal damage. (4)
In the United States, one in thirteen persons (7.7%) with
hypertension will develop hypercreatininemia; and (5)
there is the presence of proteinuria in percentages oscillat-
ing between 4 and 16% in different series of treated
hypertensive patients. All these arguments, indicate that
renal insufficiency is still prevalent in essential hyperten-
sion even considering that serum creatinine is a poor
method to estimate the evolution of renal function, espe-
cially in the initial stages of chronic renal failure.
BLOOD PRESSURE CONTROL AND RENAL
PROGNOSIS IN PRIMARY HYPERTENSION
There is no doubt that blood pressure control is needed
to avoid renal damage in primary hypertension. However,
at least two issues need to be tackled to get a further
improvement in the renal prognosis of hypertensive pa-
tients. The first is the most appropriate goal of blood
pressure control to obtain the best renal protection. The
second one is whether all antihypertensive drugs are
equally effective when renal outcome is considered.
Although the majority of experimental and clinical stud-
ies do support that lowering of arterial pressure favorably
affects the course of hypertensive renal disease [21], others
suggest that efficient control of blood pressure is not the
sole factor that is necessarily in preventing kidney damage
[22]. As already discussed, the extent of renal injury
appears to be more closely related to the height glomerular
pressure and/or to the degree of glomerular hypertrophy
than to the actual level of arterial pressure [22]. Thus, it
appears that although lowering of arterial pressure will
most likely have a protective effect against renal injury by
itself, an improved regulation of intrarenal hemodynamics
in patients in addition to blood pressure control may confer
a greater nephroprotective effect.
Another important question is whether more aggressive
arterial pressure control, that is, lowering the blood pres-
sure below the level that has afforded protection against
adverse cardiac and brain events and that is usually deemed
adequate, will have an added renoprotective effect. Surpris-
ingly, there are no studies in animals that have closely
examined this possibility. On the other hand, a few studies
in patients with nondiabetic chronic renal parenchymal
disease do suggest that more vigorous control of blood
pressure may be associated with greater renoprotection, at
least in patients with overt proteinuria and in black patients
[23]. However, a recent publication has shown that in
patients with nephrosclerosis a strict control of blood
pressure, obtained with different antihypertensive agents,
did not seem to protect renal function further [24].
The existence of an increased urinary excretion of albu-
min in arterial hypertension correlated with blood pressure
levels, which was decreased with antihypertensive therapy,
was described more than two decades ago by Parving et al
[25]. These authors described how with the use of diuretics
and beta-blockers the decrease in the levels of blood
pressure was accompanied by a parallel drop in urinary
albumin excretion rate. This finding has been amply con-
firmed later and the increase in proteinuria when hyper-
tension is present has been attributed to the transmission to
the glomeruli of the elevated systemic pressure. According
to this statement any antihypertensive therapy has the
capacity to decrease proteinuria when it coexists with
arterial hypertension.
Recently the Modification of Diet in Renal Disease
Study [26], besides supporting the concept that proteinuria
is an independent risk factor for the progression of renal
disease, has shown how a strict blood pressure control is
accompanied by a significant reduction in proteinuria that
correlated with a slower subsequent decline in glomerular
filtration rate. This finding led the authors to suggest a
target blood pressure of less than 125/75 mm Hg (mean
blood pressure or renal perfusion pressure , 92 mm Hg)
for patients with proteinuria of more than 1 g/day. When
proteinuria was between 0.25 and 1 g/day the suggested
target was less than 130/80 mm Hg (mean blood pressure or
renal perfusion pressure , 98 mm Hg). Nevertheless, this
conclusion did not pay attention to the type of antihyper-
tensive drugs used to obain the control of blood pressure.
In fact, the good results obtained in the group with a strict
blood pressure control could be ascribed to a higher
percentage of patients receiving an angiotensin converting
enzyme inhibitor in the group with the lower goal of blood
pressure control [26]. This is particularly apparent accord-
ing to the data recently published containing a secondary
analysis of the MDRD Study [27].
Interestingly, in essential hypertension it has been de-
scribed that hypertensive renal damage correlates better
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with diastolic than with systolic blood pressure [28]. The
results of the renal aspects of the HOT Study [29], where
patients are randomly assigned to one of three different
goals of diastolic blood pressure control (,90, , 85, ,80
mm Hg) will contribute to elucidate more on this aspect of
antihypertensive therapy.
Recently, the Joint National Comitee Reports (JNC-VI)
have added a new classification based on blood pressure
stage and risk groupings that is directly linked to treatment
and treatment goals [30]. Thus, this empiric classification
stratifies patients with hypertension into three risk groups:
Group A (patients with normal blood pressure or stages 1,
2, or 3 hypertension without clinical cardiovascular disease,
target organ damage, or other risk factors), group B
(patients with hypertension and at least 1 risk factor, but no
diabetes mellitus), and group C (patients with hypertension
and clinical manifestation of cardiovascular disease or
target organ damage). The goal of BP control should be to
decrease and maintain systolic BP below 140 mm Hg and
diastolic BP below 90 mm Hg and lower if tolerated, while
controlling other modifiable risk factor for cardiovascular
disease. Nevertheless, the threshold to start antihyperten-
sive drug therapy has been lowered to 130/85 mm Hg when
some degree of renal failure is present [30]. This threshold
indicates that whenever renal damage is present the goal of
BP control should be lower than 130/85 mm Hg. This goal
might be achieved by reducing sodium intake (,100 mmol/
day) plus antihypertensive drugs. In this sense, all classes of
antihypertensive drugs are effective, and in most cases,
multiple drugs are needed.
EFFECT OF ANTIHYPERTENSIVE DRUGS ON THE
COURSE OF HYPERTENSIVE RENAL DISEASE
Another issue is whether all antihypertensive drugs are
equally effective when renal outcome is considered. The
question exists of whether certain antihypertensive agents
may afford an additional degree of renal protection in
addition to the beneficial effects that can be provided solely
by the reduction in arterial pressure.
Theorically, since multiple mechanisms are involved in
the progression of hypertensive renal injury, it may be
expected that certain agents or therapeutic regimens will
confer greater nephroprotection than other, at the same
level of arterial pressure reduction. Indeed, a number of
experimental and clinical studies indicated that some
agents, particulary the ACE inhibitors, may be superior to
the others in affording nephroprotection [31, 32].
On the other hand, a number of other studies have
suggested the nephroprotective capacity of any antihyper-
tensive drug or regimen is directly related to its antihyper-
tensive efficacy. Thus, Griffin, Picken and Bidani compared
the glomeruloprotective effects of ACE inhibition and
triple therapy in a rat remnant kidney model [33]. The
results of the study have shown that the glomerular injury
in individual rats was strongly related to their overall
averaged arterial pressure, particulary with the frequency
of systolic pressure readings over 150 mm Hg. Taken as a
group, those rats treated with an ACE inhibitor had the
lowest glomerular injury score but they also had the lowest
overall averaged blood pressure. Similary, the results of a
recent meta-analysis [34] demonstrated that ECA inhibi-
tors were more effective than other antihypertensive drugs
in reducing the progression of nondiabetic renal disease.
However, the data indicated that both systolic and diastolic
blood pressures were found to be lower in those patients
receiving ACE inhibitor.
In contrast, better outcomes of renal function have been
attained when converting enzyme inhibitors have been used
both in diabetic [35] and non-diabetic [36] nephropathies.
In essential hypertension, converting enzyme inhibitors
have been shown to be more effective than diuretics,
beta-blockers, and calcium antagonists to reduce urinary
albumin excretion [37]. Furthermore, these drugs have
been shown to facilitate the regression of the remodeling
and to improve endothelial function in resistance arterioles
[32] of human hypertensives. Such an effect could account
for the recent description in a randomized double-blind
study that cilazapril differs from atenolol by its capacity to
slow the rate of progression of chronic renal failure in
patients with essential hypertension during a three year
follow-up [31]. Similar positive effects on small arterioles in
the coronary and renal vascular beds after therapy with
converting enzyme inhibitors and calcium antagonists have
been reported [38]. Therefore, although evidence has ac-
cumulated to suggest that ACE inhibitors may offer better
nephroprotection than other agents, further studies are
essential before the question is resolved.
Recently, a new class of antihypertensive drugs, angio-
tensin II receptor antagonist, were shown to provide similar
beneficial effects as the ACE inhibitors using various
models of renal injury. There are data avaible to show that
angiotensin II receptor antagonists also afford nephropro-
tection in patients. However, one study demonstrated that
losartan was more effective in reducing proteinuria in
elderly hypertensive patients with or without non-insulin
dependent diabetes mellitus than the calcium antagonist
felodipine [39].
The capacity of calcium channel blockers to preserve
renal function has been extensively studied in both exper-
imental animals and hypertensive patients. There seems to
exist differences between the different subclasses of cal-
cium channel blockers when the prognosis of renal function
is considered. In this sense, the behavior of dihydropiri-
dines could be significantly different from that of the other
subclasses represented by verapamil and diltiazem. The last
two could exhibit antiproteinuric and renoprotective activ-
ities that dihydropiridines could not possess, unless systolic
arterial blood pressure is reduced to levels below 110 mm
Hg [40]. However, differences in nephroprotective efficacy
have been noted not only between the different subclasses
Gonza´lez-Albarra´n et al: Blood pressure and the kidneyS-48
of calcium antagonist, but within the same class. For the
present, the available clinical studies have indicated that
the calcium antagonists do not adversely affect renal func-
tion in patients with nondiabetic renal insufficiency, and
also indicate that they may be more effective in preventing
or ameliorating progressive renal injury than some other
classes of antihypertensive drugs.
On the other hand, the JNC-VI clearly states that
diuretics and b-blockers should be “preferred” as first step
therapy [32], since patients using these drugs have demon-
strated a reduced morbidity and mortality from stroke and
coronary heart disease. Data on the effects of diuretics on
renal function in hypertensive renal disease are very scarce.
In general, the studies suggest that diuretic theraphy might
not be beneficial. Furthermore, experimental data suggest
that hydrochlothiazide in L-NAME treated spontaneous
hypertensive rats (SHR) further impaired glomerular dy-
namics and actually aggravated the proteinuria and glomer-
ular pathology in L-NAME treated SHR [41]. The results
of both experimental and clinical studies [37, 42] indicate
that, in most instances, b-blockers effectively control blood
pressure but fail to positively affect the course of glomer-
ular filtration rate, renal plasma flow, or proteinuria in
subjects with renal failure.
In summary, in essential hypertension renal, vasculature
participates in the alterations of the systemic vascular
function and structure that accompany arterial hyperten-
sion. Such participation could contribute initially to the
increase in blood pressure by impeding a normal renal
handling of sodium. Later on, the renal vasculature suffers
the consequences of a persintently elevated blood pressure
and nephrosclerosis can develop. Interestingly, it has been
shown that those parameters indicating the presence of an
alteration in renal function, such as increased serum creat-
inine levels or the presence of microalbuminuria and
proteinuria, are independent predictors of increased car-
diovascular morbidity and mortality [43]. This indicates
that the parameters used commmonly to measure renal
function have to be considered in any stratification of
cardiovascular risk for hypertensive patients. Therapeutic
implications can be derived from all these facts. First, we
need to know the best level of blood pressure control to
obtain the optimum protection for the kidney. Second, the
possibility of preventing hypertensive kidney damage by
early treatment of hypertensive patients who are at risk has
to be considered, in particular those patients presenting
with microalbuminuria. Finally, the results of numerous
studies clearly indicate that adequate arterial pressure
control, irrespective of the agent used to control pressure,
exerts a nephroprotective action in terms of slowing the
rate of decline in renal excretory function and reducing
proteinuria if present. However, data derived from exper-
imental and clinical studies suggest that certain antihyper-
tensive agents, notably ACE inhibitors, may have a better
nephroprotective effect that is partly independent of their
antihypertensive action. However, further studies are nec-
essary to definitively resolve these issues.
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